Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that its Phase 3 XPORT-EC-042 trial evaluating selinexor as a maintenance therapy in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE